Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1993-12-27
|
| pubmed:abstractText |
Seventy-seven consecutive patients (mean age 62 years) with episodes of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) after acute myocardial infarction (AMI) were evaluated to assess the long-term efficacy of first-line amiodarone treatment and to identify clinical and laboratory factors associated with a high risk of death or arrhythmia recurrence. The presenting arrhythmia was VT in 41 cases (53%) and VF in 36 (47%). VT or VF occurred between the 4th and 90th day after AMI in 45 cases (58%) and later (more than 90 days) in the remaining 32 (42%). The mean number of arrhythmic episodes was 4.2. Forty patients (52%) were in New York Heart Association (NYHA) class I or II, and 37 (48%) were in class III or IV. Mean left ventricular ejection fraction was 32%; ventricular aneurysm was present in 41 subjects. Most patients had multivessel coronary artery disease. Amiodarone was administered as a first-choice drug in all patients, in combination with other antiarrhythmic drugs in 14. By ventricular stimulation after loading doses of amiodarone, sustained VT was inducible in 46 (62%) and noninducible in 28 (38%). During a mean follow-up of 28 months the incidence of cardiac mortality at 1, 3, and 5 years was 21%, 37%, and 47%; of sudden death was 7%, 19%, and 23%; of nonfatal VT recurrence was 13%, 13%, and 24%, respectively. The overall incidence of amiodarone side effects was 35%.2+ was a weak predictor only by univariate analysis (p = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0920-3206
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
683-9
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8241012-Adult,
pubmed-meshheading:8241012-Aged,
pubmed-meshheading:8241012-Aged, 80 and over,
pubmed-meshheading:8241012-Amiodarone,
pubmed-meshheading:8241012-Analysis of Variance,
pubmed-meshheading:8241012-Angiocardiography,
pubmed-meshheading:8241012-Electrophysiology,
pubmed-meshheading:8241012-Female,
pubmed-meshheading:8241012-Follow-Up Studies,
pubmed-meshheading:8241012-Humans,
pubmed-meshheading:8241012-Male,
pubmed-meshheading:8241012-Middle Aged,
pubmed-meshheading:8241012-Myocardial Infarction,
pubmed-meshheading:8241012-Prognosis,
pubmed-meshheading:8241012-Recurrence,
pubmed-meshheading:8241012-Risk,
pubmed-meshheading:8241012-Tachycardia, Ventricular,
pubmed-meshheading:8241012-Treatment Outcome,
pubmed-meshheading:8241012-Ventricular Fibrillation
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction.
|
| pubmed:affiliation |
Istituto di Cardiologia, Ospedale S.M. della Misericordia, Udine, Italy.
|
| pubmed:publicationType |
Journal Article
|